The acquisition time of infection: a determinant of the severity of hepatitis C virus-related liver disease in renal transplant patients

Clin Transplant. 2009 Sep-Oct;23(5):723-31. doi: 10.1111/j.1399-0012.2009.01017.x. Epub 2009 Jun 30.

Abstract

Background: The aim of this study was to compare the clinical and histopathological course of HCV infection acquired before and during or after renal transplantation.

Methods: According to HCV status, 197 RT patients were divided into three groups. At the time of RT, anti-HCV antibody was positive in 47 patients (pre-RT HCV group). In 27 patients, in whom anti-HCV negative at the time of RT, anti-HCV and/or HCV RNA was found to be positive following an ALT elevation episode after RT (post-RT HCV group). Both anti-HCV and HCV RNA were negative at all times in remaining 123 patients (control group).

Results: Liver biopsy was performed in 31 of 47 patients in pre-RT and 24 of 27 in post-RT HCV group after RT. Duration of follow-up was similar in all groups with a mean of 7.1 +/- 4.0 yr. Ascites and encephalopathy were seen in only post-RT HCV group (22%). Histological grade (6.5 +/- 2.7 vs. 4.1 +/- 1.4) and stage (2.0 +/- 1.5 vs. 0.8 +/- 0.8) was significantly severe in post-RT HCV group (p < 0.01). Three patients died due to liver failure in post-RT HCV group.

Conclusions: HCV infection acquired during or after RT shows a severe and rapidly progressive clinicopathological course, which is significantly different from pre-transplant anti-HCV positive patients.

MeSH terms

  • Adult
  • Alanine Transaminase / metabolism
  • Female
  • Follow-Up Studies
  • Graft Rejection / immunology
  • Graft Rejection / pathology
  • Graft Survival / immunology
  • Hepacivirus / pathogenicity*
  • Hepatitis C / pathology
  • Hepatitis C / virology*
  • Hepatitis C Antibodies / metabolism
  • Humans
  • Immunosuppression Therapy
  • Kidney Transplantation*
  • Liver Cirrhosis / pathology
  • Liver Cirrhosis / virology*
  • Male
  • Postoperative Complications / virology*
  • RNA, Viral / genetics
  • Survival Rate
  • Time Factors

Substances

  • Hepatitis C Antibodies
  • RNA, Viral
  • Alanine Transaminase